According to the transition notice published in February 2023, the Department of Health and Human Services (HHS) is planning for the federal Public Health Emergency for COVID-19, declared under Section 319 of the Public Health Service Act, to expire at the end of the day on May 11, 2023. The FDA’s Emergency Use Authorizations (EUAs) for COVID-19 products, including tests, vaccines, and treatments, will not be affected (see guidance). Certain FDA COVID-19-related guidance documents for industry will end or be temporarily extended (see FDA Guidance Documents Related to Coronavirus Disease 2019 (COVID-19). In addition, Public Readiness and Emergency Preparedness (PREP) Act liability protections may be impacted.